Clinical & Experimental Metastasis最新文献_第5页

Molecular mechanisms of sensitivity and resistance to radiotherapy. 放疗敏感性和耐药性的分子机制。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-17 DOI: 10.1007/s10585-023-10260-4

Jessica L Xing, Baldassarre Stea

{"title":"Molecular mechanisms of sensitivity and resistance to radiotherapy.","authors":"Jessica L Xing, Baldassarre Stea","doi":"10.1007/s10585-023-10260-4","DOIUrl":"10.1007/s10585-023-10260-4","url":null,"abstract":"The molecular mechanisms underlying sensitivity and resistance to radiotherapy is an area of active investigation and discovery as its clinical applications have the potential to improve cancer patients' outcomes. In addition to the traditional pathways of radiation biology, our knowledge now includes molecular pathways of radiation sensitivity and resistance which have provided insights into potential targets for enhancing radiotherapy efficacy. Sensitivity to radiotherapy is influenced by the intricate interplay of various molecular mechanisms involved in DNA damage repair, apoptosis, cellular senescence, and epigenetics. Translationally, there have been several successful applications of this new knowledge into the clinic, such as biomarkers for improved response to chemo-radiation. New therapies to modify radiation response, such as the poly (ADP-ribose) polymerase (PARP) inhibitors, derived from research on DNA repair pathways leading to radiotherapy resistance, are being used clinically. In addition, p53-mediated pathways are critical for DNA damage related apoptosis, cellular senescence, and cell cycle arrest. As the understanding of genetic markers, molecular profiling, molecular imaging, and functional assays improve, these advances once translated clinically, will help propel modern radiation therapy towards more precise and individualized practices.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"517-524"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical applications of circulating tumor cells in patients with solid tumors. 循环肿瘤细胞在实体瘤患者中的临床应用。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-28 DOI: 10.1007/s10585-024-10267-5

Daniel J Smit, Svenja Schneegans, Klaus Pantel

引用次数: 0

How much do we know about the metastatic process? 我们对转移过程了解多少？

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-03-23 DOI: 10.1007/s10585-023-10248-0

Carolina Rodriguez-Tirado, Maria Soledad Sosa

{"title":"How much do we know about the metastatic process?","authors":"Carolina Rodriguez-Tirado, Maria Soledad Sosa","doi":"10.1007/s10585-023-10248-0","DOIUrl":"10.1007/s10585-023-10248-0","url":null,"abstract":"Cancer cells can leave their primary sites and travel through the circulation to distant sites, where they lodge as disseminated cancer cells (DCCs), even during the early and asymptomatic stages of tumor progression. In experimental models and clinical samples, DCCs can be detected in a non-proliferative state, defined as cellular dormancy. This state can persist for extended periods until DCCs reawaken, usually in response to niche-derived reactivation signals. Therefore, their clinical detection in sites like lymph nodes and bone marrow is linked to poor survival. Current cancer therapy designs are based on the biology of the primary tumor and do not target the biology of the dormant DCC population and thus fail to eradicate the initial or subsequent waves of metastasis. In this brief review, we discuss the current methods for detecting DCCs and highlight new strategies that aim to target DCCs that constitute minimal residual disease to reduce or prevent metastasis formation. Furthermore, we present current evidence on the relevance of DCCs derived from early stages of tumor progression in metastatic disease and describe the animal models available for their study. We also discuss our current understanding of the dissemination mechanisms utilized by genetically less- and more-advanced cancer cells, which include the functional analysis of intermediate or hybrid states of epithelial-mesenchymal transition (EMT). Finally, we raise some intriguing questions regarding the clinical impact of studying the crosstalk between evolutionary waves of DCCs and the initiation of metastatic disease.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"275-299"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant therapy for resectable melanoma. 可切除黑色素瘤的新辅助治疗。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-28 DOI: 10.1007/s10585-023-10263-1

Cimarron E Sharon, Giorgos C Karakousis

引用次数: 0

Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment. 黑色素瘤前哨淋巴结：最佳治疗的必要条件。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-02 DOI: 10.1007/s10585-023-10254-2

Mark B Faries

{"title":"Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment.","authors":"Mark B Faries","doi":"10.1007/s10585-023-10254-2","DOIUrl":"10.1007/s10585-023-10254-2","url":null,"abstract":"Lymphatic metastasis is the dominant route of initial spread for most solid tumors. For many such malignancies, including melanomas, surgical treatment previously included removal of all potentially draining regional lymph nodes (elective node dissection). The advent of lymphatic mapping and sentinel lymph node (SLN) biopsy allowed accurate pathologic assessment of the metastatic status of regional nodes and spared patients full dissection if their SLN was clear. In melanoma, recent clinical research has demonstrated that complete lymph node dissection is not clinically beneficial, even for patients with sentinel node metastases and that patients with high-risk primary melanomas benefit from adjuvant systemic immunotherapy, even without nodal disease. These two changes in the standard of care have led to some interest in abandoning surgical nodal staging via the sentinel lymph node biopsy procedure. However, this appears to be premature and potentially detrimental to optimal patient management. The ongoing value of sentinel node biopsy stems from its ability to provide critically important prognostic information as well as durable regional nodal disease control for most patients with nodal metastases, even in the absence of complete dissection of the basin. It also provides an opportunity to identify novel prognostic and predictive immunologic and molecular biomarkers. While it is certainly possible that additional changes in melanoma therapy will make sentinel lymph node biopsy obsolete in the future, at present it remains a minimally invasive, low morbidity means of improving both staging and outcomes.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"369-374"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139080508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells 更正：CXCL2-CXCR2轴介导结肠癌细胞的αV整合素依赖性腹膜转移

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-07-27 DOI: 10.1007/s10585-024-10302-5

Mattias Lepsenyi, Nader Algethami, Amr A. Al-Haidari, Anwar Algaber, Ingvar Syk, Milladur Rahman, Henrik Thorlacius

引用次数: 0

Forty years on: a brief history of clinical and experimental metastasis. 四十年：临床和实验转移简史。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-03-23 DOI: 10.1007/s10585-024-10281-7

Jonathan P Sleeman, Jörg Haier

引用次数: 0

Membrane Lipid Replacement for reconstituting mitochondrial function and moderating cancer-related fatigue, pain and other symptoms while counteracting the adverse effects of cancer cytotoxic therapy. 膜脂替代物用于重建线粒体功能，缓解癌症相关的疲劳、疼痛和其他症状，同时抵消癌症细胞毒疗法的不良影响。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-06-16 DOI: 10.1007/s10585-024-10290-6

Garth L Nicolson, Gonzalo Ferreira de Mattos

{"title":"Membrane Lipid Replacement for reconstituting mitochondrial function and moderating cancer-related fatigue, pain and other symptoms while counteracting the adverse effects of cancer cytotoxic therapy.","authors":"Garth L Nicolson, Gonzalo Ferreira de Mattos","doi":"10.1007/s10585-024-10290-6","DOIUrl":"10.1007/s10585-024-10290-6","url":null,"abstract":"Cancer-related fatigue, pain, gastrointestinal and other symptoms are among the most familiar complaints in practically every type and stage of cancer, especially metastatic cancers. Such symptoms are also related to cancer oxidative stress and the damage instigated by cancer cytotoxic therapies to cellular membranes, especially mitochondrial membranes. Cancer cytotoxic therapies (chemotherapy and radiotherapy) often cause adverse symptoms and induce patients to terminate their anti-neoplastic regimens. Cancer-related fatigue, pain and other symptoms and the adverse effects of cancer cytotoxic therapies can be safely moderated with oral Membrane Lipid Replacement (MLR) glycerolphospholipids and mitochondrial cofactors, such as coenzyme Q10. MLR provides essential membrane lipids and precursors to maintain mitochondrial and other cellular membrane functions and reduces fatigue, pain, gastrointestinal, inflammation and other symptoms. In addition, patients with a variety of chronic symptoms benefit from MLR supplements, and MLR also has the ability to enhance the bioavailability of nutrients and slowly remove toxic, hydrophobic molecules from cells and tissues.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"199-217"},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer. 肺癌患者的不良预后与癌症相关单核细胞群中细胞角蛋白阳性 CTC 的主动吞噬有关。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-02-28 DOI: 10.1007/s10585-024-10270-w

A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe

{"title":"Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.","authors":"A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe","doi":"10.1007/s10585-024-10270-w","DOIUrl":"10.1007/s10585-024-10270-w","url":null,"abstract":"High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"219-228"},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastases. 乳腺癌细胞的糖基化特征可能代表多器官转移的克隆变异。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-01-09 DOI: 10.1007/s10585-023-10253-3

Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Kaori Denda-Nagai, Katrin Ishii-Schrade, Haruhiko Fujihira, Masaaki Abe, Miki Noji, Shigeyuki Shichino, Mitsue Saito, Tatsuro Irimura

{"title":"Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastases.","authors":"Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Kaori Denda-Nagai, Katrin Ishii-Schrade, Haruhiko Fujihira, Masaaki Abe, Miki Noji, Shigeyuki Shichino, Mitsue Saito, Tatsuro Irimura","doi":"10.1007/s10585-023-10253-3","DOIUrl":"10.1007/s10585-023-10253-3","url":null,"abstract":"Glycosylation changes of cancer cells are known to be associated with malignant progression and metastases and potentially determine the organ-selective nature of metastasis as theorized by Paget (Lancet 1:571-573, 1889). Cellular glycans play a variety of roles in the processes of metastasis and may be unique to the cells that metastasize to different organs. We analyzed the glycosylation profiles of the primary tumor and tumors metastasized to lymph node, liver, lung, brain, bone, thyroid, kidney, adrenal, small intestine and pancreas in an autopsy case of breast cancer employing a lectin microarray with 45 lectins. Clustering analysis of the data revealed that metastatic breast cancer cells were categorized into several clusters according to their glycosylation profiles. Our results provide a biological basis to understand differential phenotypes of metastatic breast cancer cells potentially reflecting clonal origin, which does not directly reflect genomic or genetic changes or microenvironmental effects but connects to glycosylation profiles.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"267-270"},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0